On Winning Track: Complementary Research on Vertex, Ignyta, Novartis, Boeing and TransCanada

NEW YORK, December 30, 2014 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Vertex (NASDAQ: VRTX), Ignyta (NASDAQ: RXDX), Novartis (NYSE: NVS), Boeing (NYSE: BA), and TransCanada (NYSE: TRP). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

VRTX Research Report: ( http://get.analystsreview.com/pdf/?c=Vertex&d=30-Dec-2014&s=VRTX ),

RXDX Research Report: ( http://get.analystsreview.com/pdf/?c=Ignyta&d=30-Dec-2014&s=RXDX ),

NVS Research Report: ( http://get.analystsreview.com/pdf/?c=Novartis&d=30-Dec-2014&s=NVS ),

BA Research Report: ( http://get.analystsreview.com/pdf/?c=Boeing&d=30-Dec-2014&s=BA ),

TRP Research Report: ( http://get.analystsreview.com/pdf/?c=TransCanada&d=30-Dec-2014&s=TRP ).

============

--

Analyst Update: Drug Approvals, Orphan Drug Designations, Successful Aircraft Testing, and Acquisition

Reviewed by: Rohit Tuli, CFA®  

The US stock markets on Monday ended the day on a fairly flat note, as gains were curbed when an early rally in energy stocks was lost due to tumbling oil prices. U.S. crude settled down $1.12 at $53.61 a barrel. While the NASDAQ remained flat at 4,806.91, the S&P 500 posted its 53rd record close of the year on Monday at 2,090.57, up 0.09%. Dow Jones Industrial Average however edged 0.09% lower at 18,038.23. The European stock markets on Monday closed on a mixed note. Greek stocks and bonds slumped after politicians in the country failed for a third time to endorse Prime Minister Antonis Samaras' preferred candidate. Following the rally in the US markets on optimism about the U.S. economic outlook, the Asian stock market rose broadly on Monday. Chinese and Hong Kong shares extended recent gains in reaction to Friday's announcement by the People's Bank of China on easing liquidity requirements at banks starting next year.

Vertex Pharmaceuticals Inc. (Vertex) announced that its KALYDECO drug is now approved for use in people with cystic fibrosis (CF) ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene - a disease which affects approximately 500 people in the U.S. Find out more about the latest FDA approval for Vertex's KALYDECO drug in our comprehensive research report.

Ignyta, Inc. (Ignyta) announced that its lead product candidate entrectinib for the treatment of neuroblastoma has been granted both orphan drug designation and rare pediatric disease designation by the U.S. health regulator. Ignyta said that the designations highlight the potential for entrectinib to address unmet needs of patients with rare cancers. Click on our research report to know more about Ignyta's lead product candidate.

Novartis AG (Novartis) announced that Japan has become the first country to approve its psoriasis drug Cosentyx (secukinumab). Novartis said that the Japanese regulator has approved Cosentyx for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who are not adequately responding to systemic therapies (except for biologics). Know more about the scope for Novartis' psoriasis drug in Japan, along with expected approvals for its use in the U.S. in our research report.

Boeing Company (Boeing) and the U.S. Air Force have successfully completed the first flight of the KC-46 tanker test program. Boeing is building four test aircraft - two 767-2Cs and two KC-46A Tankers, as part of a contract awarded in 2011 to design and develop the Air Force's next-generation tanker aircraft. Know more about Boeing's latest successful aircraft test program in our research report.

TransCanada Corporation (TransCanada) announced that it has acquired eighth Ontario solar facility, Liskeard 1, from Canadian Solar Solutions Inc. (Canadian Solar). The latest acquisition takes TransCanada's total investment in its Ontario solar program to over $450 million. Read more about TransCanada's new acquired Ontario solar facility in our exclusive research report.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED